Technology

ISA Pharmaceuticals is pioneering the development of Synthetic Long Peptides (SLP®) as rationally designed off-the-shelf immunotherapeutics for the treatment of cancer and persistent virus infections. ISA’s SLP® technology can be widely applied against a multitude of viral and non-viral targets, and can provide multiple products for the treatment of cancer and persistent virus infections.

In addition, ISA’s AMPLIVANT® technology, which is based on a proprietary and synthetic toll-like receptor (TLR) agonist, establishes a new generation of chemically defined and potent immunotherapeutics for the treatment of a variety of diseases.